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Abstract 
The concentration of total vitamin B12 in serum is not a sufficiently sensitive or specific indicator for the reliable 
diagnosis of vitamin B12 deficiency. Victor Herbert proposed a model for the staged development of vitamin B12 defi-
ciency, in which holotranscobalamin (HoloTC) is the first indicator of deficiency. Based on this model, a commercial 
immunoassay has been controversially promoted as a replacement for the total vitamin B12 test. HoloTC is cobalamin 
(vitamin B12) attached to the transport protein transcobalamin, in the serum, for delivery to cells for metabolism. 
Although there have been many published reports supporting the claims for HoloTC, the results of some studies were 
inconsistent with the claim of HoloTC as the most sensitive marker of vitamin B12 deficiency. This review examines the 
evidence for and against the use of HoloTC, and concludes that the HoloTC immunoassay cannot be used to measure 
vitamin B12 status any more reliably than total vitamin B12, or to predict the onset of a metabolic deficiency, because 
it is based on an erroneous hypothesis and a flawed model for the staged development of vitamin B12 deficiency. The 
author proposes an alternative model for the development of vitamin B12 deficiency.
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Background
Herbert’s model
In his Herman Award Lecture of 1986, Victor Herbert 
proposed his Sequential stages in the development of vita-
min B12 deficiency (Herbert 1987). Herbert’s hypothesis, 
describing the Biochemical and hematological sequence 
of events as negative vitamin B12 balance progresses, two 
decades later formed the basis for the introduction of the 
commercial holotranscobalamin (HoloTC, Active B12) 
immunoassay for the diagnosis of vitamin B12 deficiency.
The concentration of total vitamin B12 in serum is not 
a sufficiently sensitive or specific indicator for the reli-
able diagnosis of vitamin B12 deficiency (Herbert 1987, 
1994; Hølleland et  al. 1999; Snow 1999; Oh and Brown 
2003; Solomon 2005; Herrmann and Obeid 2008, 2013; 
Schrempf et al. 2011; Heil et al. 2012). Herbert observed 
that, as with iron and folate, the range of normal concen-
trations of serum total vitamin B12 for an individual is 
narrower than the range of normal for a population (Her-
bert 1987): “the laboratory test result becomes abnormal 
for the individual before it exceeds the range of normal 
for the laboratory”. As observed by Snow “As knowledge 
has accumulated, the limitations of such tests as serum 
vitamin levels … have become apparent”.
The two metabolites of vitamin B12, homocysteine 
(tHcy) and methylmalonic acid (MMA) have been pro-
posed as more sensitive than total serum vitamin B12, for 
the diagnosis of vitamin B12 deficiency (Hølleland et  al. 
1999; Snow 1999; Oh and Brown 2003). In support of the 
use of these metabolites Oh and Brown say that “use of 
a low serum vitamin B12 level as the sole means of diag-
nosis may miss up to one half of patients with actual 
tissue B12 deficiency”. In advocating the use of methyl-
malonic acid, Hølleland et al. state that “Our data empha-
size the poor diagnostic utility of low and low-normal 
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s-cobalamin assay results and call for more sensitive and 
specific markers of cobalamin deficiency. s-MMA meets 
these criteria”. Solomon (2005) differed, finding that 
methylmalonic acid and homocysteine were also unreli-
able for the diagnosis of vitamin B12 deficiency.
Even now, after decades of research, there is still no 
agreed gold-standard test for vitamin B12 deficiency. As 
recently stated by Aparicio-Ugarriza et al. (2014): “There 
is no consensus in the literature about cut-off points for 
blood vitamin B12 reference ranges and its associated 
metabolites.” It is against the background of this unmet 
need that the holotranscobalamin (HoloTC, Active B12) 
immunoassay has been offered as a solution.
Holotranscobalamin (HoloTC) is cobalamin (vitamin 
B12) attached to the transport protein transcobalamin 
(TC), in the serum, for delivery to cells for metabolism. 
The absorption and transport of vitamin B12 is described 
in detail in Neale (1990). Recent developments in under-
standing the role of HoloTC in the assimilation and 
metabolism of vitamin B12 are explained in detail by 
Quadros (2010). Fedosov (2010, 2013) has produced a 
mathematical model for the biochemical markers of vita-
min B12 deficiency, including HoloTC.
Herbert proposed serum holotranscobalamin (Hol-
oTC) as an earlier and more sensitive indicator of vita-
min B12 deficiency than total vitamin B12 (Herbert 1987, 
1994). According to Herbert (1994): “Low concentra-
tions of holoTCII occur before low concentrations of 
total serum vitamin B-12 or before deficiency”. This is 
based on two properties of HoloTC; the small percent-
age of total vitamin B12 existing as HoloTC, and the 
short half-life of HoloTC. According to Herbert (1994), 
HoloTC comprises only 20 % of serum total vitamin B12; 
this metabolically active portion is carried to all cells on 
the transport protein transcobalamin (TC). The remain-
ing 80 % (holohaptocorrin, HoloHC) is the metabolically 
inert component carried on the liver storage protein hap-
tocorrin (HC). According to Herbert (1994), HoloTC has 
a short half-life of only 6 min compared to 240 h for Hol-
oHC. There is disagreement about the actual half-life of 
HoloTC, as discussed later in this review, but the consen-
sus is that it is far shorter than that of HoloHC.
According to Herbert’s 1986 model (Herbert 1987), 
vitamin B12 deficiency develops in a sequence of four 
distinct stages, with changes in specific biochemical and 
haematological markers defining the borders between 
them (Fig.  1; Table  1). The earliest sign of vitamin B12 
deficiency is marked by the change from Normal to Nega-
tive B12 Balance, with HoloTC concentration falling from 
>22 to <15  pmol/L, and TC saturation falling from >5 
to <5 %. Haematology is normal for the first two stages; 
initial abnormal haematology, in the form of neutrophil 
hypersegmentation, appears in stage 3; overtly abnormal 
haematology in the form of neutrophil hypersegmenta-
tion, macroovalocytes, elevated MCV and low haemo-
globin, appears in stage 4. MMA is possibly increased in 
stage three and definitely increased in stage four.
From his 1986 model, Herbert concluded that “By 
measuring holo TC II one can diagnose negative vitamin 
B-12 balance, a stage which precedes the stage of B-l2 
depletion”, and thus proposed HoloTC to be more sensi-
tive than total serum vitamin B12 as an indicator of the 
onset of vitamin B12 deficiency. Herzlich and Herbert 
(1988) stated: “The data suggest low holo TC II indicates 
negative B12 balance early in the development of tissue 
depletion of B12 … We believe that this parameter pro-
vides a new tool for assessing nutritional status in equiv-
ocal states”. Wickramasinghe and Fida (1993) supported 
Herbert’s hypothesis, concluding that “Our data support 
the model of developing B12 deficiency proposed by Her-
bert and his colleagues and their view that a proper study 
of B12 values should include not only measurements of 
total serum B12 but also of holoTCII concentration”. Neale 
(1990) more cautiously commented on the hypothesis: “A 
reduction in the circulating concentration of holo-TCII 
may be the earliest sign of vitamin B12 deficiency. This 
potentially important observation awaits confirmation”.
Herbert modified his model in 1990 and again in 
1994 (Herbert 1994), adding two Positive Balance stages 
before the Normal stage, and changing the HoloTC and 
TC thresholds (Fig.  2; Table  1). Homocysteine, the sec-
ond metabolite of vitamin B12, is included in this revised 
model. These changes broaden the range of analytes con-
sidered while reducing the relative differences in analyte 
concentrations, particularly HoloTC concentration and 
TC saturation, between stages. The range of HoloTC 
concentration thresholds has been reduced significantly, 
with the difference between normal and deficient condi-
tions much less clear.
The most important effect of the reduction in the range 
of HoloTC concentration thresholds is in the diagnosis 
of the very earliest progression from normality to defi-
ciency; the detection of Negative vitamin B12 Balance 
(Table  1). In Herbert’s original 1986 model, HoloTC 
concentration needs to fall from >22 to <15  pmol/L, to 
progress from Normal to Negative Vitamin B12 Balance, 
a fall of 33  %. In the revised model of 1994, HoloTC 
concentration needs to fall from >37 to <30  pmol/L, to 
progress from Normal to Early Negative Vitamin B12 Bal-
ance, a fall of 20 %. Because of the smaller percentage fall 
in HoloTC required to change from normal to abnormal 
in the revised model, despite the absolute value of the dif-
ferences between these stages remaining the same, the 
diagnosis of Negative Vitamin B12 Balance now requires 
greater precision and accuracy in the individual assay and 
greater certainty of the HoloTC cut-off levels.
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Fig. 1 Herbert’s 1986 model for sequential stages in the development of vitamin B12 deficiency. This simplified model was derived from Herbert 
(1987)
Table 1 Herbert’s hypothesis—differences between 1986 and 1994 models
Data in this table was derived from Herbert (1987, 1994)
HoloTC concentration converted from pg/mL to pmol/L, using formula from Herbert (1987): HoloTC (pmol/L) = HoloTC (pg/mL) × 0.74
Two stages preceding “Normal”, added by Herbert in the 1994 model, omitted from this table
Analyte Model Deficiency stage
1 2 3 4
1986 Normal Negative  
B12 balance
B12 depletion B12-deficient  
erythropoiesis
B12-deficiency anaemia
1994 Normal Early negative  
B12 balance





HoloTC (pmol/L) 1986 >22 <15 <15 <9 <9
HoloTC (pmol/L) 1994 >37 <30 <30 <30 <30
TC saturation (%) 1986 >5 <5 <2 <1 <1
TC saturation (%) 1994 >5 <4 <4 <4 <4
HoloHC (pmol/L) 1986 >111 >111 <111 <74 <74
HoloHC (pmol/L) 1994 >133 >133 <111 <74 <74
MMA high 1986 No No No ? Yes
MMA high 1994 No No No ? Yes
tHcy high 1986 – – – – –
tHcy high 1994 No No No Yes Yes
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Commercialisation of the HoloTC immunoassay
Commercialisation of the HoloTC test commenced when 
the company Axis-Shield of Norway, and the University 
of Aarhus in Denmark, participated in a joint venture: 
Project E! 2263—HOLOTC “Development Of Diagnos-
tic Test For Holotc”, from April 2000 to February 2005 
(Eureka 2000). The stated objective of the project was 
to develop a new test that is simple and reliable for the 
diagnosis of vitamin B12 deficiency. Nexo et  al. (2002b), 
from the University of Aarhus, reported a new method 
for measurement of HoloTC. Ulleland et al. (2002), spon-
sored by Axis-Shield, reported having developed the first 
reliable assay for HoloTC.
The HoloTC test as an alternative to the total vitamin 
B12 assay was further supported, from October 2002 to 
March 2006, by the European Union demonstration 
project: QLK3-CT-2002-01775 “Demonstration of the 
clinical utility of holotc as an early marker of vitamin 
b12 deficiency” (European Union 2002). The project was 
coordinated by the University of Aarhus in Denmark; 
other participants were Axis-Shield and the University 
of Bergen in Norway, the University of Oxford in the UK 
and Trinity College Dublin in Ireland. The stated aims of 
the project were to: “demonstrate the analytical perfor-
mance of this assay in 4 countries; to show its superiority 
to conventional methods for assessment of vitamin B12 
status; and to demonstrate its value in older patients with 
depression or dementia”.
As the commercial partner in the development of the 
HoloTC immunoassay, Axis-Shield has published several 
documents in support of the HoloTC test as an alterna-
tive to the total vitamin B12 assay (Axis-Shield 2007a, b, 
2012, 2014a, b). In their presentation of February 2007, 
Axis-Shield cites Herbert’s model for the sequential 
development of vitamin B12 deficiency. A modified ver-
sion of Herbert’s (1994) hypothesis, as a simplified dia-
gram, was provided to support the claim that HoloTC is 
a more sensitive indicator of vitamin B12 deficiency than 
Fig. 2 Herbert’s (1994) model for sequential stages in the development of vitamin B12 deficiency. This simplified model was derived from Herbert 
(1994)
Page 5 of 20Golding  SpringerPlus  (2016) 5:668 
is total vitamin B12. The same diagram was used by Ralph 
Green in his detailed presentation to the Specialty Labs 
Web Conference of December 2007, when supporting the 
case for using HoloTC for the diagnosis of vitamin B12 
deficiency (Green 2007).
Based on Herbert’s models, in which the HoloTC con-
centration falls as the vitamin B12 status progresses from 
Normal to Negative Vitamin B12 Balance as the first 
evidence of deficiency, Axis-Shield (2007a) claims that 
“Active-B12 levels react early in the process” and “Active-
B12 levels are low in patients with biochemical signs of 
vitamin B12 deficiency”.
Axis-Shield (2007a) cites Herrmann et al. (2003a), say-
ing “Data suggests improved identification of B12 defi-
cient patients with Active-B12 compared to total serum 
B12”.
Axis-Shield initially marketed their own immunoassay 
kit for HoloTC, then formed partnerships with manu-
facturers of automated immunoassay analysers. In 2006 
Axis-Shield marketed their RIA (radioimmunoassay) kit 
for HoloTC (Axis-Shield 2007b), the first commercially 
available test for holotranscobalamin. In 2007 Abbott 
Laboratories, in partnership with Axis-Shield, com-
menced marketing their MEIA (Microparticle Enzyme 
Immunoassay) for assay of HoloTC on the AxSYM ana-
lyser (Abbott Laboratories 2006; Axis-Shield and Abbott 
Laboratories 2006a, b, 2007a, b; Brady et al. 2007, 2008). 
Pry (2006), for Abbott Laboratories, presented Holo 
Transcobalamin; A Predictor of Vitamin B12 Status. Brady 
et  al. (2008), employees of Axis-Shield, stated that “The 
AxSYM Active B12 assay allows rapid, precise, sensitive, 
specific, and automated measurement of human hol-
oTC in serum and plasma”. In 2011 Abbott Laboratories 
broadened the application for the HoloTC kit to include 
their automated Architect high-throughput immunoas-
say analyser (Abbott Laboratories 2011). IBL Interna-
tional (2013) markets an enzyme-immunoassay (ELISA) 
kit, and Siemens is currently developing a HoloTC kit for 
use on their ADVIA Centaur immunoassay system.
Review
Summary of original research and previous reviews
Results from previous original research, for HoloTC sen-
sitivity and specificity compared to total vitamin B12, are 
summarised in Table  2. Many authors concluded that 
HoloTC is an earlier and more sensitive indicator of the 
onset of vitamin B12 deficiency than total vitamin B12 
(Table  3, column 1). Other original studies have con-
cluded that there is no significant improvement in sen-
sitivity of HoloTC in comparison to total vitamin B12 
(Table  3, column 2). Quotations from original reports 
are available in tables in Microsoft Excel spreadsheet file, 
Additional file 3.
In March 2012, a group of nine internationally recog-
nised experts issued an Expert’s Consensus Statement in 
support of the use of the HoloTC test: “Emerging evi-
dence indicates that holotranscobalamin (Active-B12) 
is a more reliable marker of a patient’s B12 status than 
is serum vitamin B12” (Herrmann et  al. 2012) (Table  4). 
However, there is not consensus between all experts, as 
demonstrated by a report on the NHANES (National 
Health and Nutrition Survey) roundtable on biomarkers 
of vitamin B12 status (Yetley et al. 2011). The report rec-
ommended total vitamin B12 as the marker for circulating 
vitamin B12 because of the need for additional perfor-
mance studies of the HoloTC test.
Reviews, presentations, commentary and letters, on the 
use of HoloTC as an earlier and more sensitive indica-
tor of vitamin B12 deficiency than total vitamin B12, have 
been mixed. Several authors supported the claim that 
HoloTC was superior (Green 2011; Greibe et  al. 2012; 
Nexo and Hoffmann-Lücke 2011). Others raised con-
cerns about the clinical utility of the test (Carmel 2002, 
2011, 2012; Devalia 2006; Devalia et  al. 2014; Hvas and 
Nexo 2006; Oberley and Yang (2013). Herrmann et  al. 
(2003b) and Herrmann and Obeid (2007, 2008) recom-
mended the combined use of methylmalonic acid (MMA) 
and HoloTC. Questioning the superiority of the HoloTC 
test, Carmel (2002) stated that “what low holo-TC con-
centrations really tell us remains elusive.”
HoloTC problems
There are four problematic aspects of HoloTC, where 
there are major differences between authors: the value 
of the half-life of HoloTC; the correlation between Hol-
oTC and total vitamin B12; sensitivity of HoloTC to recent 
absorption of vitamin B12; the value of HoloTC cut-off to 
detect negative vitamin B12 balance. The latter two dif-
ferences are the most important because they raise the 
questions of what it is that HoloTC concentration actu-
ally indicates, and whether or not it is possible to use it to 
reliably detect the early onset of vitamin B12 deficiency.
Half‑life
Although the proponents of HoloTC, as an early indicator 
of vitamin B12 deficiency, cite the shorter half-life of Hol-
oTC compared to HoloHC as a factor, there is no general 
agreement on the absolute value (Table 5). In supporting 
their case for HoloTC, Axis-Shield (2007b) states: “The 
markedly shorter half-life for HoloTC of 1–2 hours ver-
sus 9 days for HoloHC makes a decrease of HoloTC one 
of the earliest markers of cobalamin deficiency”; Herbert 
(1994) gives values of 6  min for HoloTC and 240  h for 
HoloHC. Whether the half-life of HoloTC is minutes or 
hours is not significant compared to the generally agreed 
240  h for HoloHC. Therefore, although the differences 
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between authors are considerable and should be resolved, 
they do not invalidate the case for using HoloTC.
Correlation with total vitamin B12
The correlation between HoloTC and total vitamin B12 
concentrations, in reports of original research, varies 
widely between authors (Table  6). Bamonti et  al. (2010) 
reported a weak correlation (r =  0.42) whereas Augous-
tides-Savvopoulou et al. (2007) reported a very strong cor-
relation (r = 0.882). Although most researchers reported 
a single value for r, there were notable exceptions. Her-
rmann and Obeid (2013) reported separate values of r for 
low or high values of total vitamin B12 (r = 0.524 for low 
B12; r = 0.403 for high B12). Refsum et al. (2006) reported 
separate values for male and female subjects (r = 0.65 for 
male; r = 0.61 for female). The differences between find-
ings, for correlation coefficient, are important because 
they reflect different sensitivity and/or specificity relation-
ships between HoloTC and total vitamin B12. A very high 
correlation, over a wide range of values, would imply that 
HoloTC could not detect the onset of vitamin B12 defi-
ciency any earlier than total vitamin B12. However, a very 
low correlation would not necessarily mean that HoloTC 
is a more sensitive marker of the transition from normal 
to negative vitamin B12 balance.
Sensitivity to recent absorption
The reported sensitivity of the HoloTC concentra-
tion to recent absorption of vitamin B12 varies between 
authors (Table  7), leading to the important question 
about whether HoloTC concentration indicates long-
term status or recent absorption of vitamin B12 or both. 
Axis-Shield and Abbott Laboratories (Axis-Shield and 
Abbott Laboratories 2006a, 2007a; Axis-Shield 2007a) 
cite Chen et al. (2005), stating that HoloTC reflects vita-
min B12 status “independent of recent absorption of the 
vitamin”. Chen et al. (2005) actually concluded that “Met-
abolic cobalamin status is a major determinant of serum 
holo-TC II. Absorption status may have mild influence as 
well”. Axis-Shield (2012) cite Nexo: “newly absorbed vita-
min B12 occurs as holoTC, and therefore an increase in 
holoTC upon oral loading with vitamin B12 can be used 
to judge the capacity for uptake of the vitamin”. Several 
authors found the issue to be problematic (Bamonti et al. 
2010; Loikas 2007; Carmel 2002, 2012). Bamonti et  al. 
(2010) cited the conflicting findings of Chen et al. (2005) 
and Bor et  al. (2004). Loikas (2007) commented on the 
apparently contradictory promotion of HoloTC as “the 
most sensitive and specific indicator of early vitamin B12 
deficiency” and the proposed use of HoloTC as “a marker 
of vitamin B12 absorption”, concluding that “Reconciling 
Table 2 Sensitivity and specificity—HoloTC versus B12—original research data
Clarke et al. (2007) compared the HoloTC immunoassay to two assay methods for total vitamin B12: Beckman and Centaur
Scott et al. (2007) compared the HoloTC immunoassay to three assay methods for total vitamin B12: Beckman, Centaur and micro assays
AUC, area under ROC curve for HoloTC or total vitamin B12; ROC curve, Receiver Operating Characteristic = sensitivity versus (1 − specificity) = true positive versus 
false positive (Miller et al. 2006); Cut-off, analyte and cut-off value used to define vitamin B12 deficiency
Reference Sensitivity Specificity Cut-off AUC
Bamonti et al. (2010) 0.74 0.52 HoloTC < 40 pmol/L 0.75
Clarke et al. (2007)  
(definite deficiency)
0.771 versus 0.757 0.761 versus 0.724 MMA > 0.75 μmol/L 0.85 versus 0.76
Clarke et al. (2007)  
(probable deficiency)
0.647 versus 0.626 0.792 versus 0.748 MMA > 0.45 μmol/L 0.79 versus 0.87
Goringe et al. (2006) HoloTC < 38 pmol/L 0.75 versus 0.72
Heil et al. (2012) 0.83 versus 0.64 0.60 versus 0.64 MMA > 0.45 μmol/L 0.78 versus 0.70
Herrmann et al. (2003a) 0.87 versus 0.45 0.75 versus 0.98 MMA > 0.271 μmol/L 0.879 versus 0.836
Herrmann and Obeid (2013) 0.72 versus 0.72 0.54 versus 0.41 MMA > 0.300 μmol/L 0.714 versus 0.632
Hvas and Nexo (2003) 1.0 0.89
Hvas and Nexo (2005) MMA > 0.75 μmol/L 0.90 versus 0.85
Lindemans et al. (2007) MMA > 0.26 μmol/L 0.80 versus 0.68
Lloyd-Wright et al. (2003) MMA > 0.75 μmol/L 0.87 versus 0.86
Miller et al. (2006) holoTC < 35 pmol/L 0.828 versus 0.816
Obeid and Herrmann (2007a) 0.72 MMA > 0.300 μmol/L 0.71 versus 0.60
Palacios et al. (2013) 0.44 versus 0.20 0.94 versus 0.94 HoloTC < 35 pmol/L 0.75 versus 0.69
Schrempf et al. (2011) 0.563 versus 0.662 0.505 versus 0.621 MMA > 47 μg/L 0.66 versus 0.72
Scott et al. (2007) MMA > 0.75 μmol/L 0.85 versus 0.75, 
0.74, 0.72
Valente et al. (2011) 0.55 versus 0.33 0.96 versus 0.95 Red cell cobalamin  
<33 pmol/L
0.90 versus 0.80
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these two phenomena is problematic because, although 
frequently coexisting, they are not identical”. In his edito-
rial, Carmel (2002) observed that “The favoured hypoth-
eses have been that low holo-TC is either an early sign 
of general cobalamin insufficiency or specific evidence 
of decreased absorption of cobalamin. The distinc-
tion between these two very separate explanations has 
blurred, particularly as advocacy became more enthusi-
astic, but it is not an idle distinction. This central issue 
and many other questions need resolution”.
No agreed cut‑off
Another important problem is that there is no agreement 
on a single value for the cut-off level for the minimum 
concentration of HoloTC, as required to distinguish 
between normal vitamin B12 status and the first stage of 
deficiency (Table 8). Morkbak et al. (2005) quoted a range 
of 11–41  pmol/L for eight European studies, stating: 
“There is no consensus concerning the choice of refer-
ence intervals for holoTC”. According to Heil et al. (2012): 
“large discrepancies exist with regard to the choice of cut-
off value for HoloTC (range 20–45 pmol/L), which makes 
data interpretation difficult”. In their review, Aparicio-
Ugarriza et  al. (2014) found that, in 69 studies between 
1992 and 2014, researchers quoted HoloTC concentra-
tion cut-offs from 20 to 50 pmol/L.
Furthermore, several researchers quote a grey zone, or 
indeterminate range of cut-off values for HoloTC con-
centration (Table 8). Herrmann and Obeid (2007) quote 
a grey zone for HoloTC cut-offs, of 40–70  pmol/L; they 
later changed this to 23–75  pmol/L (Herrmann and 
Obeid 2013). Lloyd-Wright et  al. (2003) say that defi-
ciency is likely for a HoloTC concentration <25 pmol/L, 
and unlikely for >50  pmol/L, leaving an indeterminate 
range of 25–50  pmol/L. Sobczyńska-Malefora et  al. 
Table 3 Sensitivity and  specificity—HoloTC versus  B12—
original research conclusions
Positive, neutral or negative conclusions are as understood by this author to be 
the intention of authors of cited article
Quotations from original reports are available in tables in Microsoft Excel 
spreadsheet file, Additional file 3
Positive conclusions Negative or neutral conclusions
Augoustides-Savvopoulou et al. 
(2007)
Al Aisari et al. (2010)
Bhat et al. (2009) Chen et al. (2005)
Black et al. (2006) Clarke et al. (2007)
Bor et al. (2004) Goringe et al. (2006)Čabarkapa et al. (2007) Loikas et al. (2003)
Fragasso et al. (2012) Loikas (2007)
Heil et al. (2012) Miller et al. (2006)
Herrmann et al. (2003a) Nilsson et al. (2004)
Herrmann et al. (2005) Palacios et al. (2013)
Herrmann and Obeid (2013) Remacha et al. (2014)
Hvas and Nexo (2003) Schrempf et al. (2011)
Hvas and Nexo (2005) Sobczyńska-Malefora et al. (2014)
Lee et al. (2009) van Asselt et al. (2003)
Lindemans et al. (2007)
Lindgren et al. (1999)
Lloyd-Wright et al. (2003)
Lobreglio et al. (2008)
Morkbak et al. (2007)
Nexo et al. (2002a)
Obeid and Herrmann (2007a)
Scott et al. (2007)
Serefhanoglu et al. (2008)
Sikaris (2010)
Valente et al. (2011)
Vanpoucke et al. (2007)
Woo et al. (2010)
Table 4 Signatories to “Expert’s Consensus Statement”
From Herrmann et al. (2012)
Consensus Statement: “Emerging evidence indicates that holotranscobalamin 
(Active-B12) is a more reliable marker of a patient’s B12 status than is serum 
vitamin B12”
Signatory Institution
Wolfgang Herrmann Saarland University
Rima Obeid Saarland University
Ralph Green University of California
Donald Jacobsen Cleveland Clinic
Dominic Harrington St. Thomas’ Hospital
Per Magne Ueland University of Bergen
Jan Lindemans Erasmus Medical Center
Ebba Nexø Aarhus University Hospital
Anne Molloy Trinity College Dublin
Table 5 Half-life of HoloTC
Reference Half-life HoloTC
Axis-Shield (2007b) 1–2 h
Bor et al. (2004) 1–12 h
Carmel and Agrawal (2012) Minutes
Chatthanawaree (2011) 1 h
Chen et al. (2005) Few hours
Green (2007) 6 min
Herbert (1994) 6 min
Herrmann et al. (2003a) 6 min
Hvas et al. (2005) 1–2 h
Lindgren et al. (1999) 1–2 h
Loikas et al. (2003) 60 min
Quadros (2010) 1–2 h
von Castel-Roberts et al. (2007) 18 h
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(2014) found that HoloTC concentrations in the range 
of 25–50  pmol/L could not be used to predict the vita-
min B12 status as defined by MMA concentration. 
Valente et  al. (2011) reported an indeterminate zone 
of 20–30  pmol/L for HoloTC concentrations. In their 
BJH guideline, Devalia et  al. (2014) recommended that 
“Serum holotranscobalamin has the potential as a first-
line test, but an indeterminate ‘grey area’ may still exist”.
The HoloTC test appears to suffer from a similar limita-
tion to that found for total vitamin B12; the range of nor-
mal values for an individual is much narrower than the 
range of normal for a population (Herbert 1987). Accord-
ing to McCaddon et  al. (2003), referring to the HoloTC 
test: “the dispersion of values for any individual will span 
only a small part of any reference interval”.
The absence of an agreement on a single cut-off value 
for HoloTC, for diagnosis of vitamin B12 deficiency, is 
inconsistent with a widely stated reason for supporting 
the use of this test in place of total vitamin B12: that there 
is a wide indeterminate range for total vitamin B12. In pro-
moting their HoloTC assay, Axis-Shield (2007a) state this 
inadequacy of the total vitamin B12 test: “There is a grey 
zone between approximately 151–300 pmol/L B12 where 
there is likely to be misclassification of B12 status if relying 
on total serum B12 alone.” If there is no universally agreed 
single cut-off value for a minimum HoloTC concentration, 
this test appears to have the same flaw as total vitamin 
B12. Is it possible to reliably detect the early onset of vita-
min B12 deficiency, i.e. the transition between Herbert’s 
sequential stages from Normal to Early Negative B12 Bal-
ance, if there is no agreed single cut-off value for HoloTC?
Potential for data manipulation to promote HoloTC
Area Under Curve (AUC)
Where the Area Under Curve (AUC) is reported for 
Receiver Operating Characteristic (ROC) curves, the 
selection of the reference analyte and value of the refer-
ence cut-off determines the relative areas under the curve 
(Table 2). For example, Heil et al. (2012) produced three 
ROC curves where different cut-off levels of MMA were 
used to define vitamin B12 deficiency, demonstrating how 
the choice of reference cut-off level determines the differ-
ence in AUC for HoloTC compared to total vitamin B12. 
With the lowest MMA cut-off, of >0.32 µmol/L, the AUC 
was 0.70 for HoloTC, compared to 0.63 for total vitamin 
Table 6 Correlation between total vitamin B12 and HoloTC
Herrmann and Obeid (2013) reported three values for r: for the whole range of 
total vitamin B12; for low values of vitamin B12; for high values of vitamin B12
Refsum et al. (2006) reported separate values for r for males and females
Reference HoloTC versus B12 correlation 
coefficient (r)
Al Aisari et al. (2010) 0.765
Augoustides-Savvopoulou et al. (2007) 0.882
Bamonti et al. (2010) 0.42Čabarkapa et al. (2007) 0.53
Chen et al. (2005) 0.45
Clarke et al. (2007) 0.61
Fragasso et al. (2012) 0.64
Goringe et al. (2006) 0.63 (r2 = 0.397)
Herrmann et al. (2003a) 0.75
Herrmann and Obeid (2013) 0.577 (whole), 0.524 (low B12), 
0.403 (high B12)
Hvas and Nexo (2005) 0.71
Lee et al. (2009) 0.6591
Lloyd-Wright et al. (2003) 0.75
Lobreglio et al. (2008) 0.495
Loikas et al. (2003) 0.80
Loikas (2007) 0.78
Nexo et al. (2002b) 0.45
Palacios et al. (2013) 0.65
Refsum et al. (2006) 0.65 (male), 0.61 (female)
Schrempf et al. (2011) 0.577–0.637
Scott et al. (2007) 0.5
Vanpoucke et al. (2007) 0.53 (r2 = 0.28)
Table 7 Sensitivity to recent absorption
Quotations from original reports are available in tables in Microsoft Excel 
spreadsheet file, Additional file 3
Reference Dependence on recent 
absorption
Axis-Shield and Abbott  
Laboratories (2006a)
Independent
Axis-Shield and Abbott Laboratories (2007a) Independent
Axis-Shield (2007a) Independent
Axis-Shield (2012) Dependent
Bamonti et al. (2010) Problematic
Bhat et al. (2009) Dependent
Bor et al. (2004) Dependent
Bor et al. (2005) Dependent
Carmel (2002) Problematic
Carmel (2012) Problematic
Chen et al. (2005) Both?
Green (2011) Both
Hvas et al. (2005) Independent
Hvas et al. (2007) Dependent
IBL International (2013) Independent
Lindgren et al. (1999) Dependent
Loikas (2007) Problematic
Morkbak et al. (2005) Dependent
Nexo et al. (2002a) Dependent
Nexo and Hoffmann-Lücke (2011) Both
Robinson et al. (2011) Both
von Castel-Roberts et al. (2007) Dependent
Page 9 of 20Golding  SpringerPlus  (2016) 5:668 
B12. At their preferred MMA cut-off, of >0.45  µmol/L, 
the AUC was 0.78 for HoloTC, compared to 0.70 for total 
vitamin B12. When the MMA cut-off was increased to 
>0.77 µmol/L, the AUC was 0.92 for HoloTC, compared 
to 0.73 for total vitamin B12.
By increasing the MMA cut-off, the difference in AUC 
between HoloTC and total vitamin B12 is increased (Heil 
et  al. 2012, Figure  1), improving the apparent perfor-
mance of HoloTC, but many more vitamin B12 deficient 
patients will be misdiagnosed as normal. The next stage 
of the process, selection of the total vitamin B12 and Hol-
oTC cut-offs, is a trade-off between sensitivity and speci-
ficity (Heil et al. 2012, Figure 4).
The trade‑off between sensitivity and specificity
As noted by this author (Golding 2016), it is possi-
ble to alter the apparent relative sensitivity of any pair 
of analytes by selectively changing the cut-off value of 
one or both of them. As demonstrated in that experi-
ment, selecting different cut-off values for total vitamin 
B12 changed the relative sensitivities of HoloTC and 
total vitamin B12; the same applies to the cut-off value 
for HoloTC. When the HoloTC cut-off is increased, the 
sensitivity to vitamin B12 deficiency is increased, but the 
specificity of the test is reduced, increasing the number 
of false positive results. Conversely, if the HoloTC cut-off 
is decreased, the specificity of the test is increased, but 
the sensitivity of the test is reduced, increasing the num-
ber of false negative results.
From their ROC charts, Heil et  al. (2012, Figure  3) 
selected MMA > 0.45 µmol/L to define vitamin B12 defi-
ciency. With a HoloTC cut-off value of <21 pmol/L, the 
specificity was impressively high at 88 % but the sensitiv-
ity was only 64 % (Heil et al. 2012, Figure 4b). By select-
ing the best trade-off between sensitivity and specificity 
for HoloTC, with a HoloTC cut-off value of <32 pmol/L, 
Table 8 HoloTC reference intervals and cut-offs




Abbott Laboratories (2006) 37
Abbott Laboratories (2011) 35
Al Aisari et al. (2010) 9–123










Bamonti et al. (2010) 40
Black et al. (2006) 23–100
Brady et al. (2007) 35
Chen et al. (2005) 46–356 30
Clarke et al. (2007) 45
Fragasso et al. (2012) 35
Goringe et al. (2006) 16 (diagnostic),  
38 (laboratory)
Green (2007, 2011) 35
Heil et al. (2012) 32
Herbert (1987) 22
Herbert (1994) 37
Herrmann et al. (2003a, b, 2005) 35
Herrmann and Obeid (2007) 40–70 “Grey zone”
Herrmann and Obeid (2008) 35
Herrmann and Obeid (2013) 22–76 “Grey zone”
Herrmann et al. (2003a) 35
Herrmann et al. (2005) 35
Hooshmand et al. (2012) 35
Hvas and Nexo (2003) 50
Hvas and Nexo (2005) 40
Lee et al. (2009) 42.48
Lindemans et al. (2007) 20–122
Lindgren et al. (1999) 35–160
Lloyd-Wright et al. (2003) <25 likely, >50 unlikely  
B12 deficiency
Lobreglio et al. (2008) 35
Loikas et al. (2003, 2007a, b) 37
Loikas (2007) 37–171
Miller et al. (2006) 35
Morkbak et al. (2005) 40, 11–41 (literature 
review)
37
Morkbak et al. (2007) 40–150
Nexo et al. (2002a) 40–150
Nexo et al. (2002b) 40–150
Nexo and Hoffmann-Lücke 
(2011)
40–200
Obeid and Herrmann  
(2007a, 2007b)
35
Palacios et al. (2013) 35
Table 8 continued





Refsum et al. (2006) 42–157
Remacha et al. (2014) 33.5
Schrempf et al. (2011) 42
Serefhanoglu et al. (2008) 37
Sobczyńska-Malefora et al. 
(2014)
25–50 “poor predictor 
MMA”
Valente et al. (2011) 20–30 “indeterminate 
zone”
20
van Asselt et al. (2003) 38–113
Vanpoucke et al. (2007) 37
Woo et al. (2010) 35
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they obtained an impressive HoloTC sensitivity of 83  % 
but a specificity of only 60 %. To overcome this problem, 
as did Herrmann and Obeid (2007, 2008), the authors 
suggest using MMA as a secondary test to confirm vita-
min B12 deficiency in cases where HoloTC is <32 pmol/L. 
This approach would have failed to detect any vitamin 
B12 deficiency in the subject of this author’s experiment 
(Golding 2016) because, despite overt metabolic distur-
bance evident from raised MMA concentration, and the 
onset of severe symptoms including peripheral neuropa-
thy, HoloTC concentration never fell below 33 pmol/L.
Contrary findings
The results of several studies did not support the claims 
that HoloTC is a significantly earlier marker of vitamin 
B12 deficiency than total B12 (Clarke et  al. 2007; Pala-
cios et al. 2013; Schrempf et al. 2011; Miller et al. 2006; 
Remacha et  al. 2014). This author, in his single-subject 
self-experiment, reported no significant difference in 
response between HoloTC and total vitamin B12 (Golding 
2016).
Contrary to Heil et al., Schrempf et al. (2011) reported 
a lower AUC for HoloTC than for total vitamin B12; 0.563 
versus 0.662 (Table  2). Their study was conducted on 
neuropsychiatric patients with vitamin B12 deficiency 
defined by MMA  >  47  µg/L (40  µmol/L). The authors 
presented the ROC curves for three patient groups: all 
patients; those with classic vitamin B12 deficiency (sub-
acute combined degeneration and/or peripheral neu-
ropathy); those with peripheral neuropathy only. In each 
grouping, the AUC for total vitamin B12 was greater than 
for HoloTC (Schrempf et al. 2011, Figure 1).
Based on their ROC results, in which the AUCs for 
HoloTC and total vitamin B12 were 0.828 and 0.816 
respectively, Miller et al. (2006) concluded that “HoloTC 
and total vitamin B12 have equal diagnostic accuracy in 
screening for metabolic vitamin B12 deficiency”. They also 
reported correlations between their results, for HoloTC 
and total vitamin B12, which were not consistent with 
Herbert’s model. For example, some patients with nor-
mal HoloTC (>35 pmol/L) were low in total vitamin B12 
(<148 pmol/L).
As observed by Herrmann and Obeid (2013), in report-
ing results of their investigation of the biological markers 
of vitamin B12 deficiency, “The shape of the ROC curve 
illustrates that the holoTC test is not sufficient to sepa-
rate between deficient and non-deficient individuals with 
high reliability”.
Remacha et  al. (2014) investigated 106 patients with 
total vitamin B12 concentration ≤200  pmol/L, defin-
ing low HoloTC as a concentration <33.5  pmol/L and 
high MMA as a concentration >0.40  µmol/L. Of the 31 
patients with normal HoloTC concentrations, 13 had 
high levels of MMA; of the 75 patients with low HoloTC 
concentrations, 27 had normal MMA. Remacha et  al. 
reported that “HoloTC was not decreased in one-third 
of patients with low Cbl, but MMA/Hcy levels were ele-
vated in half of them, reflecting Cbl deficiency.”
The problems with Herbert’s model
The absence of an agreed single value for the HoloTC 
cut-off, together with uncertainty about whether Hol-
oTC represents recent absorption of vitamin B12 or long-
term status or both, must raise questions about Herbert’s 
hypothesis. Some of the most recent original research 
challenges Herbert’s model for the “Sequential stages in 
the development of vitamin B12 deficiency”. In report-
ing their original research results, Remacha et al. (2014) 
commented that “These data do not support holoTC as 
the earliest marker of Cbl deficiency and challenge the 
classification in stages of Cbl deficiency”.
In Herbert’s revised 1994 model (Herbert 1994), the 
change from Normal to Early Negative Vitamin B12 Bal-
ance is marked by a fall in HoloTC concentration from 
>37 to <30  pmol/L. Even if it is assumed that such a 
highly precise and accurate routine clinical assay is pos-
sible, there remain two major unresolved fundamental 
problems with Herbert’s hypothesis.
Firstly, as raised by several authors, there is uncertainty 
about what HoloTC actually represents (Table 7). Does Hol-
oTC concentration indicate recent absorption of vitamin 
B12, long-term body store or both? As stated by Chen et al. 
(2005): “The concept that a test can be used to diagnose 
both deficiency and malabsorption is problematic because 
the 2 defects are not identical. If holo-TC II truly reflects 
both processes, holo-TC II changes would perforce lose all 
diagnostic specificity for either process”. For the HoloTC 
immunoassay to have any clinical value in detecting the ear-
liest onset of vitamin B12 deficiency, as Herbert intended, it 
would need to be either sensitive only to long-term status or 
be performed after a well-defined period of fasting.
Secondly, the model demands the reliable detection 
of a change in HoloTC concentration far smaller than 
the reported range of cut-off values (Table  8). As noted 
by Sobczyńska-Malefora et  al. (2014), “there has been 
little consensus with regard to the assigned cut-off to 
discriminate between replete and deficient states”. Her-
bert’s required change in HoloTC concentration from 
>37 to <30 pmol/L, to detect the earliest onset of vitamin 
B12 deficiency, is inconsistent with the reported range 
of cut-off values from 20 to 50  pmol/L. Furthermore, 
the use of various grey zones, for HoloTC concentration 
(Table  8), is inconsistent with Herbert’s hypothesis in 
which Early Negative Vitamin B12 Balance is detected by 
a universally agreed, and closely specified, fall in HoloTC 
concentration.
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Why Herbert’s model is flawed
Herbert’s model for the staged development of vita-
min B12 deficiency is based on his erroneous hypothesis 
that HoloTC will always be the first analyte to respond 
to a deficiency, and that a minimum normal concentra-
tion of HoloTC may be universally defined. How Herbert 
developed his hypothesis, and why it is flawed, is best 
explained by examining the process of gastrointestinal 
absorption and transport of vitamin B12 in humans.
Normal gastrointestinal absorption of vitamin B12
Figure 3 is a simplified diagram containing the main ele-
ments of the process of gastrointestinal absorption and 
transport of vitamin B12 in humans. In a healthy person, 
stomach acid separates food vitamin B12 from protein; 
haptocorrin (HC) from saliva then binds with the free 
vitamin B12 to form the holohaptocorrin (HoloHC) (Loi-
kas 2007, Figure 2.4). The increased pH in the duodenum 
causes the vitamin B12 to be released from the HC; intrin-
sic factor (IF), produced by parietal cells in the stom-
ach, combines with the vitamin B12 in the duodenum to 
produce IF-B12 (Loikas 2007, Figure 2.4). The IF is then 
degraded in the terminal ileum, producing free vitamin 
B12 (Seetharam and Yammani 2003, Figure  1; Andrès 
et al. 2004, Figure 1; Loikas 2007, Figure 2.4).
There is no consensus on the exact location of the pro-
duction of HoloTC and HoloHC.
According to Seetharam and Yammani (2003, Figure 1), 
and Andrès et al. (2004, Figure 1), the free B12 is bound to 
TC in the ileum to form HoloTC; they show HoloHC in 
the portal vein but do not say how or where it is formed. 
Quadros (2010) states that “The IF-Cbl absorbed in the 
distal ileum appears in the circulation bound to TC”, 
implying that all of the free B12 is bound to TC to form 
HoloTC; it is unclear from this whether the free B12 binds 
to the TC in the ileum or in the circulation. According to 
Furger (2012) “In the blood plasma Cbl is bound either 
to HC or TC, where only TC is responsible for the Cbl 
uptake into cells”; again, it is unclear where the binding 
takes place. If all of the free vitamin B12 in the ileum is 
bound to TC, regardless of whether the binding takes 
place in the ileum or in the circulation, then the HoloHC 
in the circulation must ultimately be produced from vita-
min B12 freed from the HoloTC.
The HoloTC enters the general circulation from where 
it is delivered to cells for metabolism (Seetharam and 
Fig. 3 Vitamin B12 gastrointestinal absorption. Derived from Seetharam and Yammani (2003, Figure 1), Andrès et al. (2004, Figure 1) and Loikas 
(2007, Figure 2.4)
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Yammani 2003, Figure  1; Andrès et  al. 2004, Figure  1; 
Loikas 2007, Figure 2.4; Quadros 2010; Furger 2012).
The HoloHC is passed, via the portal vein, to the 
liver where the vitamin B12 is separated from the HC 
and stored in the liver (Seetharam and Yammani 2003, 
Figure  1). When HoloTC is required for metabolism, 
some of the vitamin B12 stored in the liver is bound to HC 
and recycled via the bile (Seetharam and Yammani 2003, 
Figure 1; Loikas 2007, Figure 2.4).
Normal enterohepatic recycling of vitamin B12
Of crucial importance to this entire gastrointestinal 
absorption process is the enterohepatic recycling of the 
vitamin B12, shown in Fig.  3 as the transfer of HoloHC 
from the liver to the duodenum, in the bile. This recy-
cling is not only essential for the efficient maintenance of 
the body store of vitamin B12; it is the means by which 
the serum concentration of HoloTC is regulated. The rate 
of transfer to the duodenum of HoloHC in bile, and the 
IF from the parietal cells, controls the rate of HoloTC 
production.
This enterohepatic recycling process is shown, as a 
feedback control system, in Fig. 4. Here, the Input to the 
system is the intrinsic factor; the system Output is the 
HoloTC. The Process is the production of IF-B12 from 
the IF and vitamin B12 in the duodenum, and the bind-
ing of the B12 freed from IF in the terminal ileum with 
transcobalamin (TC) to produce holotranscobalamin 
(HoloTC). For the purposes of this discussion, the liver 
vitamin B12 store is not part of the input but considered 
to be a constant in the short-term. The Feedback signals 
control the rate of the process; details of the nature of 
these signals are beyond the scope of this review.
Failure of enterohepatic recycling and HoloTC production
If any one of the elements of this feedback control 
system suddenly fails entirely, the enterohepatic recy-
cling will stop immediately, and no HoloTC will be 
produced; for example, if the supply of intrinsic factor 
or production of bile suddenly stops or if the terminal 
ileum or duodenum are removed. Under these cir-
cumstances, Herbert’s hypothesis would be expected 
to hold true in one respect; the fall in HoloTC would 
be an early indicator of a vitamin B12 deficiency. The 
HoloHC has a far longer half-life than the HoloTC in 
serum, and there is a large store of vitamin B12 in the 
liver and red-cells, so HoloHC would fall much more 
slowly than HoloTC.
It is important to note that only a disturbance of the IF 
input, or of elements within this HoloTC feedback sys-
tem, will affect its short-term performance. Assuming 
that the liver vitamin B12 store is full, any failure ahead 
the input of IF, or after the output of HoloTC will have 
no short-term effect on the production of HoloTC. This 
Fig. 4 HoloTC feedback control. Derived from Seetharam and Yammani (2003, Figure 1), Andrès et al. (2004, Figure 1) and Loikas (2007, Figure 2.4)
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means that HoloTC will not be an early responder for 
all causes of vitamin B12 deficiency; if the enterohepatic 
cycle is not disrupted, HoloTC would remain normal 
until the liver store of HoloHC is exhausted.
HoloTC response depends on cause of vitamin B12 deficiency
The following discussion is based on this author’s inter-
pretation of available information about the operation of 
the vitamin B12 enterohepatic cycle, and the response of 
total vitamin B12, HoloTC, tHcy and MMA for different 
causes of vitamin B12 deficiency. Human experimentation 
is needed to investigate the actual responses of the ana-
lytes under these various conditions.
According to Herbert (1987, 1994), there are six pos-
sible causes of vitamin B12 deficiency; three inadequa-
cies and three excesses. These conditions, and their effect 
on the HoloTC feedback system, are listed in Table 9. A 
seventh very common cause of vitamin B12 deficiency, 
food-cobalamin malabsorption, was reported by Carmel 
(1995) and reviewed by Andrès et al. (2004); this is shown 
in Table 9 as a fourth inadequacy.
A suddenly inadequate dietary intake, for example com-
mencing a vegan diet, will not affect the enterohepatic 
cycle because it does not affect the input of intrinsic fac-
tor into the cycle until the store of HoloHC is exhausted 
i.e. it occurs ahead of the cycle. Similarly, the onset of 
inadequate utilization in the cells also will not affect the 
production of HoloTC i.e. it occurs after the cycle. In 
either case, Herbert’s model will not apply because total 
vitamin B12 will fall before HoloTC responds, and MMA 
and tHcy will commence to increase immediately after 
HoloTC falls below normal for the individual.
An increased requirement, increased excretion or 
increased destruction, would tend to cause an increase in 
the rate of enterohepatic recycling to maintain the serum 
concentration of HoloTC; if all else is equal, the cycle will 
continue to produce HoloTC until the supply of stored Hol-
oHC is consumed. Again, Herbert’s model will not hold true 
because total vitamin B12 will fall before HoloTC responds, 
and MMA and tHcy will commence to increase immedi-
ately after HoloTC falls below normal for the individual.
One inadequacy, gastrointestinal malabsorption, affect-
ing the supply of intrinsic factor, production of bile or 
absorption of the IF-B12, has the potential to halt Hol-
oTC production. HoloTC is likely to be a fast responder 
to a rapid failure such as the removal of the relevant 
part of the stomach, containing the parietal cells, or the 
removal of the duodenum or terminal ileum. In this case, 
however, MMA and tHcy would be expected to almost 
immediately increase above normal for the individual, 
so there would be no period when HoloTC is depleted 
without any metabolic disturbance, and Herbert’s model 
would not hold true.
If there is a gradual failure of supply of intrinsic factor 
to the input, in the case of Pernicious Anaemia where 
the autoimmune disease causes antibodies to attack the 
parietal cells or intrinsic factor or other slowly develop-
ing problem with gastrointestinal vitamin B12 absorption, 
the metabolic disturbance would again commence imme-
diately but MMA and tHcy would increase more slowly. 
Again, because there would be no period when HoloTC 
is depleted without any metabolic disturbance, Herbert’s 
model would not apply.
The very common case of food-cobalamin malabsorp-
tion, where gastric atrophy occurs during ageing, was 
first identified after Herbert proposed his model (Carmel 
1995; Andrès et al. 2004). This case would be similar to 
that of inadequate dietary intake, where the enterohe-
patic cycle is not disturbed because there is no effect on 
the input of intrinsic factor into the cycle until the liver 
store of HoloHC is exhausted. Because the deficiency 
occurs ahead of the cycle, there would be no period when 
HoloTC is depleted without any metabolic disturbance, 
so Herbert’s model would not hold true. If the slow onset 
of vitamin B12 deficiency in this case does cause HoloTC 
to fall significantly, and remain depleted before other 
analytes react, the published experimental results should 
demonstrate this. According to Andrès et  al. (2004), 
Table 9 Causes of vitamin B12 deficiency, and short-term effect on HoloTC production
From Herbert (1987, 1994), Carmel (1995) and Andrès et al. (2004)
Cause of vitamin B12 deficiency Classification Short-term effect 
on HoloTC production?
Inadequate dietary intake Inadequacy No
Defective gastrointestinal absorption (other than food-cobalamin absorption) Inadequacy Yes?
Defective gastrointestinal absorption (food-cobalamin malabsorption) Inadequacy No
Inadequate cellular utilization (deficiency of a cobalamin coenzyme) Inadequacy No
Increased requirement (pregnancy or hyperthyroidism) Excess No
Increased excretion (alcoholism) Excess No
Increased destruction (nutrient or drug interactions) Excess No, unless intrinsic factor 
destroyed
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>60  % of cases of vitamin B12 deficiency in the elderly 
are caused by food-cobalamin malabsorption. The stud-
ies reported by Miller et  al. (2006), Clarke et  al. (2007), 
Schrempf et al. (2011), Palacios et al. (2013) and Remacha 
et  al. (2014) all involved aged patients, so the majority 
were therefore likely to have their vitamin B12 deficiency 
caused by food-cobalamin malabsorption. If Herbert’s 
model applied to those patients, HoloTC should have 
been reported as significantly more sensitive than total 
vitamin B12, but this was not the case in those studies.
An alternative hypothesis
Introduction
This author proposes an alternative model (Fig.  5) in 
which the earliest onset of vitamin B12 deficiency, or the 
transition from Normal to Early Negative Vitamin B12 
Balance, is not defined by a fall in HoloTC concentra-
tion from above one universally specified level to below 
another. Instead, vitamin B12 deficiency is defined by a 
change, in total vitamin B12, HoloTC or metabolite con-
centrations, from what is normal for the individual.
Stages of development of vitamin B12 deficiency
The alternative model for the development of vitamin 
B12 deficiency contains only three stages: Normal; Deple-
tion; Metabolic Deficiency (Fig.  5). The Normal stage 
is defined as the condition in which the intake, and the 
internal processing, for an individual provides sufficient 
vitamin B12 to sustain all of their metabolic requirements 
and maintain their body store of vitamin B12. The Deple-
tion stage, marked by the commencement of a long-term 
fall in serum total vitamin B12 concentration, is defined as 
the condition in which the intake, or the internal process-
ing, for an individual does not provide sufficient vitamin 
B12 to sustain all of their metabolic requirements, which 
are then maintained by depleting their body store of vita-
min B12. The Metabolic Deficiency stage, marked by the 
commencement of a fall in the HoloTC concentration 
and an increase in either MMA or tHcy or both metab-
olites, is defined as the condition in which the depleted 
body store of vitamin B12, or the internal processing, for 
an individual is insufficient to sustain all of their meta-
bolic requirements.
Cellular storage of vitamin B12 and potential delays 
in metabolic response to fall in HoloTC
Herbert (1994) stated: “holoTCII will always be low 
before there is a rise in methylmalonate or homocysteine 
if that rise is due to a vitamin B-12 deficiency.” This alter-
native model proposes an additional principle; that any 
fall in HoloTC, to below normal for the individual, must 
result in a disturbed metabolism and a rise in the metab-
olites. How quickly this happens depends on how much 
vitamin B12 is stored in the cells; this varies between cell 
types; some cells, including nerve cells and some blood 
cells, have very small vitamin B12 stores. For example, 
as stated by Herbert (1994) “Lack of delivery of vitamin 
B-12 to the glial cells of the brain quickly wipes out their 
small vitamin B-12 stores, after which they become vita-
min B-12 deficient”.
This alternative hypothesis therefore assumes that, for 
at least some cell types, there will be no significant delay 
Fig. 5 Alternative model for the development of vitamin B12 deficiency. Total B12, serum total vitamin B12 concentration; HoloTC, serum hol-
otranscobalamin concentration; MMA, plasma methylmalonic acid concentration; tHcy, plasma total homocysteine concentration
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between the fall in HoloTC concentration to below nor-
mal for the individual, and the rise in MMA and/or tHcy. 
This is consistent with Herbert (1987) where, in referring 
to the timing of a fall in HoloTC and the development of 
neutrophil hypersegmentation, he states that: “when one 
follows individuals from B-12 normality into the earli-
est stages of B-12 deficiency, one discovers that both fall 
almost together in the individual. The amount of B-12 on 
the B-12 delivery protein transcobalamin II falls sharply 
and, at almost the same time (probably fractionally later), 
DNA synthesis becomes subnormal in the granulocytes.” 
Even if not all cells are affected immediately, and if the 
MMA and/or tHcy are not yet measurably abnormally 
high, the metabolism for some cell types has been dis-
turbed. Thus in this alternative model, almost immedi-
ately after the HoloTC production falls below normal for 
any reason, the Depletion stage ends and the Metabolic 
Deficiency stage commences.
Dependence of timing of HoloTC response on cause 
of vitamin B12 deficiency
The magnitude and speed of any change in HoloTC con-
centration depends on the cause of the onset of vitamin 
B12 deficiency, as well as individual variables involved in 
the absorption, transport and utilization of vitamin B12. 
Three possible cases of disruption to the enterohepatic 
cycle are considered here: failure only after exhaustion 
of vitamin B12 liver store; instantaneous failure; gradual 
failure. The following discussion is based on this author’s 
hypothesis about how the response of total vitamin B12, 
HoloTC, tHcy and MMA depends on the cause of vita-
min B12 deficiency. Human experimentation is needed to 
validate this model.
Failure only after exhaustion of vitamin B12 liver store
When there is no short-term disruption to the entero-
hepatic cycle, HoloTC concentration will be maintained 
until there is insufficient holohaptocorrin remaining to 
sustain HoloTC production. This case contains all stages 
of the general model, as shown in Fig. 5, where there is 
a significant Depletion period before the eventual failure 
of the enterohepatic cycle leads to the onset of Meta-
bolic Deficiency. The total vitamin B12 falls, but HoloTC, 
MMA and tHcy remain normal, during the Depletion 
period. When the liver store of HoloHC is consumed, 
Metabolic Deficiency commences, with the HoloTC con-
centration falling and the MMA and tHcy increasing. 
This case applies where the failure is outside of the Hol-
oTC feedback control loop (Fig. 4), for example when the 
vitamin B12 deficiency is caused by reduction in intake, or 
reduction in the utilization of the vitamin B12 in the cells 
because of a defect in the intracellular cobalamin metab-
olism. Another, very common, example of this case is 
food-cobalamin malabsorption where vitamin B12 bound 
to food protein cannot be released because of hypochlo-
rhydria due to gastric atrophy (Carmel 1995; Andrès et al. 
2004). This common cause of vitamin B12 deficiency in 
the elderly is not the same as pernicious anaemia because 
production of intrinsic factor is not affected; the patient 
is able to absorb unbound vitamin B12. Examples of such 
cases consistent with this alternative model, where vita-
min B12 deficiency was likely to be caused by gradual 
loss of gastric acid production, were those whose sub-
jects were elderly (Miller et  al. 2006; Clarke et  al. 2007; 
Schrempf et al. 2011; Palacios et al. 2013; Remacha et al. 
2014).
Instantaneous failure
If the production of HoloTC suddenly halts, because of 
an instantaneous failure of the enterohepatic cycle, for 
example as a result of the surgical removal of the pari-
etal cells of the stomach, an extreme case of the proposed 
model will apply. As shown in Fig. 6, the sudden loss of 
HoloTC will cause an almost immediate metabolic dis-
turbance and a rise in the concentration of MMA and/
or HoloTC. Thus, there will be no Depletion period in 
this case, because MMA and/or tHcy will respond almost 
instantaneously to the fall in HoloTC concentration, 
and the Metabolic Deficiency stage commences almost 
immediately.
Gradual failure
Figure  7 illustrates the case where the production of 
HoloTC gradually fails, for example as a result of loss 
of parietal cell function due to the autoimmune disease 
pernicious anaemia. As for the case of instantaneous fail-
ure, there is no Depletion period, and the Metabolic Defi-
ciency stage commences almost immediately, because 
MMA and/or tHcy will start to increase immediately 
after the HoloTC concentration falls below the normal 
level for the individual. The difference in this case is that 
the rate of change of the analytes will be slower than 
when the supply of intrinsic factor is suddenly stopped.
Consequences of questioning Herbert’s model
Questioning of Herbert’s hypothesis that HoloTC is the 
most sensitive marker of Early Negative Vitamin B12 Bal-
ance, or his model for the sequential stages in the devel-
opment of vitamin B12 deficiency, is likely to raise strong 
objections.
Firstly, any model that is based on changes from indi-
vidual normal analyte concentrations, instead of com-
parison with a universally accepted population normal, 
conflicts with the dogma that there must be a gold-stand-
ard test for vitamin B12 deficiency; either HoloTC or one 
a yet to be discovered.
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Secondly, any model that requires a comparison of cur-
rent analyte concentrations with a patient’s own normal 
levels would require proactive testing of all persons at 
risk, before the onset of any symptoms, to obtain their 
individual healthy baseline concentrations. Herbert him-
self suggested proactive testing, saying “serum holoTCIl 
should be measured every 5 y starting at age 55 because 
gradual loss of the ability to absorb vitamin B-12 occurs 
in everyone in a genetically determined, age-dependent 
pattern.” (Herbert 1994).
A potential alternative to obtaining a longitudinal 
record for individuals at risk is the use of an algorithm 
to combine the results of a one-off test of all four ana-
lytes into a single parameter. A mathematical model for 
Fig. 6 Instantaneous failure of enterohepatic recycling. Total B12, serum total vitamin B12 concentration; HoloTC, serum holotranscobalamin con-
centration; MMA, plasma methylmalonic acid concentration; tHcy, plasma total homocysteine concentration
Fig. 7 Gradual failure of enterohepatic recycling. Total B12, serum total vitamin B12 concentration; HoloTC, serum holotranscobalamin concentration; 
MMA, plasma methylmalonic acid concentration; tHcy, plasma total homocysteine concentration
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this has been devised and described in detail by Fedosov 
(2010), and further tested and refined (Fedosov 2013; 
Fedosov et al. 2015; Brito et al. 2016). This author is cau-
tious about this approach because, as with all other cur-
rent methods, it might apply well to a population but not 
necessarily to an individual. This would need extensive 
testing on a wide range of subjects, for various causes of 
vitamin B12 deficiency, before it could be validated.
Summary and conclusion
Axis-Shield and others, in promoting the commerciali-
sation of the HoloTC immunoassay, have relied on Her-
bert’s erroneous hypothesis that “Ho1oTCII falls below 
the bottom of its normal range long before total serum 
vitamin B-12 … falls below the bottom of its normal 
range”, and his flawed model for the staged development 
of vitamin B12 deficiency (Herbert 1994).
Herbert’s model is flawed because it assumes that a 
normal minimum concentration for HoloTC may be uni-
versally defined. As with total vitamin B12, evidenced by 
the failure to find such a single cut-off value for HoloTC 
and instead the discovery of a wide grey zone for HoloTC, 
the range of normal for an individual is much smaller 
than for the population. As stated by Herbert (1994): 
“What is normal for one is not normal for another”.
Herbert’s hypothesis, that HoloTC will respond early 
to vitamin B12 depletion, before the onset of a clinical 
deficiency, is erroneous because it does not take into 
account how enterohepatic recycling regulates the Hol-
oTC concentration. Where the cause of vitamin B12 
deficiency does not disrupt the enterohepatic cycle, 
HoloTC will not be an early responder to a deficiency; 
there will be a Depletion period, in which total vita-
min B12 falls, but HoloTC and the metabolites will only 
respond after the liver store is exhausted. When the 
cause of vitamin B12 deficiency does disrupt the enter-
ohepatic cycle, the HoloTC will be an early responder 
but there will be no Depletion period; the metabolites 
will respond quickly when HoloTC falls below normal 
for the individual.
The HoloTC immunoassay cannot be used to meas-
ure vitamin B12 status any more reliably than total vita-
min B12, or to predict the onset of a metabolic deficiency, 
because it is based on an erroneous hypothesis and a 
flawed model for the staged development of vitamin B12 
deficiency.
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